Early prenatal diagnosis of major cardiac anomalies in a high-risk population

2002 ◽  
Vol 22 (7) ◽  
pp. 586-593 ◽  
Author(s):  
C. Comas Gabriel ◽  
A. Galindo ◽  
J. M. Martínez ◽  
J. M. Carrera ◽  
F. Gutiérrez-Larraya ◽  
...  
Keyword(s):  
Prenatal Diagnosis ◽  
High Risk ◽  
High Risk Population ◽  
Risk Population ◽  
Cardiac Anomalies

Early diagnosis of fetal cardiac anomalies by transvaginal echocardiography in a high-risk population

2001 ◽  
Vol 1 (3) ◽  
pp. 256-261 ◽  
Author(s):  
C. Comas ◽  
C. Mortera ◽  
M. Torrents ◽  
A. Muñoz ◽  
E. Antolín ◽  
...  
Keyword(s):  
High Risk ◽  
Early Diagnosis ◽  
High Risk Population ◽  
Risk Population ◽  
Cardiac Anomalies

Evaluation of the perianal muscular complex in the prenatal diagnosis of anorectal atresia in a high-risk population

2012 ◽  
Vol 39 (5) ◽  
pp. 521-527 ◽  
Author(s):  
J. H. Ochoa ◽  
M. Chiesa ◽  
R. P. Vildoza ◽  
A. E. Wong ◽  
W. Sepulveda
Keyword(s):  
Prenatal Diagnosis ◽  
High Risk ◽  
High Risk Population ◽  
Risk Population ◽  
Anorectal Atresia

scholarly journals OP28.04: More than a gut feeling: sonographic prenatal diagnosis of imperforate anus in a high risk population

2014 ◽  
Vol 44 (S1) ◽  
pp. 130-130
Author(s):  
S. Perlman ◽  
R. Bilik ◽  
L. Leibovitch ◽  
E. Katorza ◽  
R. Achiron ◽  
...  
Keyword(s):  
Prenatal Diagnosis ◽  
High Risk ◽  
Imperforate Anus ◽  
High Risk Population ◽  
Risk Population

More than a gut feeling - sonographic prenatal diagnosis of imperforate anus in a high-risk population

2014 ◽  
Vol 34 (13) ◽  
pp. 1307-1311 ◽  
Author(s):  
Sharon Perlman ◽  
Ron Bilik ◽  
Leah Leibovitch ◽  
Eldad Katorza ◽  
Reuven Achiron ◽  
...  
Keyword(s):  
Prenatal Diagnosis ◽  
High Risk ◽  
Imperforate Anus ◽  
High Risk Population ◽  
Risk Population

Early diagnosis of fetal cardiac anomalies by transvaginal echocardiography in a high-risk population

2001 ◽  
Vol 1 (3) ◽  
pp. 256-261
Author(s):  
C. Comas ◽  
C. Mortera ◽  
M. Torrents ◽  
A. Muñoz ◽  
E. Antolín ◽  
...  
Keyword(s):  
High Risk ◽  
Early Diagnosis ◽  
High Risk Population ◽  
Risk Population ◽  
Cardiac Anomalies

scholarly journals Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Maitri Kalra ◽  
Yan Tong ◽  
David R. Jones ◽  
Tom Walsh ◽  
Michael A. Danso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Neoadjuvant Therapy ◽  
Triple Negative ◽  
Residual Disease ◽  
Disease Free Survival ◽  
Parp Inhibition ◽  
High Risk Population ◽  
Risk Population ◽  
The Impact

AbstractPatients with triple-negative breast cancer (TNBC) who have residual disease after neoadjuvant therapy have a high risk of recurrence. We tested the impact of DNA-damaging chemotherapy alone or with PARP inhibition in this high-risk population. Patients with TNBC or deleterious BRCA mutation (TNBC/BRCAmut) who had >2 cm of invasive disease in the breast or persistent lymph node (LN) involvement after neoadjuvant therapy were assigned 1:1 to cisplatin alone or with rucaparib. Germline mutations were identified with BROCA analysis. The primary endpoint was 2-year disease-free survival (DFS) with 80% power to detect an HR 0.5. From Feb 2010 to May 2013, 128 patients were enrolled. Median tumor size at surgery was 1.9 cm (0–11.5 cm) with 1 (0–38) involved LN; median Residual Cancer Burden (RCB) score was 2.6. Six patients had known deleterious BRCA1 or BRCA2 mutations at study entry, but BROCA identified deleterious mutations in 22% of patients with available samples. Toxicity was similar in both arms. Despite frequent dose reductions (21% of patients) and delays (43.8% of patients), 73% of patients completed planned cisplatin. Rucaparib exposure was limited with median concentration 275 (82–4694) ng/mL post-infusion on day 3. The addition of rucaparib to cisplatin did not increase 2-year DFS (54.2% cisplatin vs. 64.1% cisplatin + rucaparib; P = 0.29). In the high-risk post preoperative TNBC/BRCAmut setting, the addition of low-dose rucaparib did not improve 2-year DFS or increase the toxicity of cisplatin. Genetic testing was underutilized in this high-risk population.

Sign in / Sign up

Export Citation Format

Share Document